Analyst M. Ian Somaiya began covering Infinity shares with an "Overweight" rating and a price target of $53 per share. Somaiya said he thinks shares of Infinity will continue to rise as the company reports results from early clinical trials of the drug, called IPI-145. He doesn't expect the drug to be approved until 2019??????2019??
You are all missing the point. Blockbuster oncology products command a premium in the market right now. IPI-145 is not only a potential blockbuster - but INFI retains all of the rights worldwide. Yes, the drug may be many years away - but the regulatory process has been streamlined by the FDA this year - and the historical timelines for approvals are a thing of the past. Educated investors in biotech have watched companies such as Pharmacyclics and Vertex receive "Breakthrough Therapy" designation. This designation shortens the timelines significantly - and moves exceptional products to market without requiring a phase 3 trial. INFI's current valuation is cheap. You might not think so based on when they will receive revenue. However, the value of INFI on the open market is huge right now. Just ask Novartis - who just bought almost 5% of the company's outstanding shares. Do you honestly think that you know more about INFI than Novartis - the biggest drug company in the world?